New hope for lung scarring: SOLIS trial tests H01 drug
NCT ID NCT06325696
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 5 times
Summary
This study tests a drug called H01 (hymecromone) in adults with interstitial lung disease, a condition that causes lung scarring and makes breathing hard. The goal is to see if H01 can lower a marker of lung damage and improve lung function. Participants take the drug as a tablet twice daily for 12 weeks and attend clinic visits for tests like breathing tests and a 6-minute walk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NIEHS Clinical Research Unit (CRU)
RECRUITINGResearch Triangle Park, North Carolina, 27709, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI catch lung scarring that doctors might miss?
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can arm workouts boost oxygen use in lung disease?
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues